Ads
related to: treating vaginal atrophy without estrogenneueve.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
A 2021 study examined the effectiveness of aloe vera vaginal cream for the treatment of atrophic vaginitis. This randomized, double-blind, controlled trial compared the effectiveness of Aloe Vera vaginal cream to estrogen vaginal cream in treating vaginal atrophy in 60 postmenopausal women. [39]
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, [1] [2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).
Ospemifene is a selective estrogen receptor modulator (SERM) [4] acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy." [5]
It was approved for prevention and treatment of osteoporosis and was the first clinically available SERM to prevent both osteoporosis and breast cancer. [9] Ospemifene was approved on February 26, 2013, for the treatment of moderate to severe dyspareunia, which is a symptom, due to menopause, of vulvar and vaginal atrophy.
The treatment saved my life but also pushed me into medically-induced menopause at the age of just 37. ... While a reported 50 to 60 percent of postmenopausal people experience vaginal atrophy ...
[22] [23] For use in menopausal hormone therapy, E2/DRSP is specifically approved to treat moderate to severe vasomotor symptoms (hot flashes), vaginal atrophy, and postmenopausal osteoporosis. [24] [25] [26] The drospirenone component in this formulation is included specifically to prevent estrogen-induced endometrial hyperplasia. [27]
Ads
related to: treating vaginal atrophy without estrogenneueve.com has been visited by 10K+ users in the past month